Pharma Equity Group A/S (CPH:PEG)

Market Cap	157.13M
Revenue (ttm)	n/a
Net Income (ttm)	-24.42M
Shares Out	1.23B
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,725,109
Average Volume	1,382,729
Open	0.1280
Previous Close	0.1280
Day's Range	0.1255 - 0.1395
52-Week Range	0.0706 - 0.3200
Beta	0.80
RSI	68.29
Earnings Date	Aug 14, 2025

About Pharma Equity Group

Pharma Equity Group A/S, through its subsidiary, Reponex Pharmaceuticals A/S, a clinical-stage biopharmaceutical company, develops treatments for diseases that have patient and social impact for which current therapy is lacking or in need of improvement. Its products under development that are in Phase II clinical trials include RNX-011 for the treatment of bacterial peritonitis; RNX-021, RNX-022, and RNX-023 for the treatment of Ulcus Cruris chronic skin ulcers; RNX-041 for the treatment of inflammatory bowel diseases, such as chrons and pouch...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 1
• Stock Exchange: Copenhagen Stock Exchange
• Ticker Symbol: PEG